Retevmo Approval History

FDA Approved: Yes (First approved May 8, 2020)
Brand name: Retevmo
Generic name: selpercatinib
Dosage form: Capsules
Company: Eli Lilly and Company
Treatment for: Non-Small Cell Lung Cancer, Thyroid Cancer

Retevmo (selpercatinib) is a kinase inhibitor for the treatment of patients with advanced RET fusion-positive non-small cell lung cancer (NSCLC), RET-mutant medullary thyroid cancer (MTC) and RET fusion-positive thyroid cancer.

Development History and FDA Approval Process for Retevmo

Date	Article
May  8, 2020	FDA Approves Retevmo (selpercatinib) for Patients with Advanced RET-Driven Lung and Thyroid Cancers
Jan 29, 2020	Lilly Receives FDA Priority Review for the Selpercatinib New Drug Application
Dec 30, 2019	Lilly Opens Phase 3 Clinical Trial for Selpercatinib (LOXO-292) in RET-Mutant Medullary Thyroid Cancer
Sep 29, 2019	Lilly Announces Positive Registrational Data for Selpercatinib (LOXO-292) in Heavily Pretreated RET-Altered Thyroid Cancers
Sep  9, 2019	Lilly Announces Positive Results for Selpercatinib (LOXO-292), Demonstrating a 68 Percent Objective Response Rate and Sustained Durability in Heavily Pretreated RET Fusion-Positive Non-Small Cell Lung Cancer
Oct 15, 2018	Loxo Oncology Announces Receipt of Breakthrough Therapy Designation from U.S. Food and Drug Administration for LOXO-292 for the Treatment of RET Fusion-Positive Thyroid Cancer
May 10, 2017	Loxo Oncology Announces Enrollment of First Patient in Phase 1 Clinical Trial for Highly Selective RET Inhibitor, LOXO-292

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer